Dimensional Fund Advisors LP Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Dimensional Fund Advisors LP lifted its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 35.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 111,051 shares of the company’s stock after buying an additional 29,105 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.19% of Pyxis Oncology worth $173,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in Pyxis Oncology by 88.1% during the 4th quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after purchasing an additional 140,498 shares during the last quarter. Renaissance Technologies LLC lifted its position in Pyxis Oncology by 83.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock valued at $458,000 after acquiring an additional 133,018 shares during the last quarter. Marshall Wace LLP lifted its position in Pyxis Oncology by 35.7% during the fourth quarter. Marshall Wace LLP now owns 157,953 shares of the company’s stock valued at $246,000 after acquiring an additional 41,594 shares during the last quarter. Aristides Capital LLC acquired a new position in Pyxis Oncology during the 4th quarter valued at approximately $193,000. Finally, Barclays PLC increased its stake in Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock valued at $121,000 after purchasing an additional 12,924 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $1.21 on Friday. The firm’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.63. Pyxis Oncology, Inc. has a one year low of $0.83 and a one year high of $5.39. The firm has a market cap of $74.96 million, a P/E ratio of -1.17 and a beta of 1.15.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, research analysts predict that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PYXS. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.